Otsuka and Ionis Achieve Primary Endpoint in Phase 3 Trial of FUS-ALS Drug Ulefnersen
Success of Phase 3 Trial for Ulefnersen, an Antisense Oligonucleotide Targeting FUS Mutations
Ulefnersen (development code ION363), a drug candidate for FUS mutation-associated Amyotrophic Lateral Sclerosis (FUS-ALS) being co-developed by Otsuka Pharmaceutical (Otsuka Holdings, 4578) and Ionis Pharmaceuticals (IONS), has met its primary endpoint with statistical significance in the Phase 3 FUSION study. This Phase 3 study is considered a significant academic advance, as the molecular targeted therapy based on the antisense oligonucleotide (ASO) mechanism—which directly inhibits the production of FUS mutant proteins—demonstrated both suppression of functional decline and extension of survival in patients with refractory hereditary ALS.
Demonstration of Clinical Efficacy and Biomarker Improvement via Joint Rank Analysis
The FUSION Phase 3 trial established a Joint Rank Analysis of the time to death or permanent ventilator use, time to rescue therapy, and change in Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score up to 505 days of dosing as the primary endpoint, demonstrating a decisive improvement with p=0.0005 compared to the control group. Statistical significance was also achieved in key secondary endpoints, including the reduction of serum Neurofilament Light chain (NfL) concentrations (a marker of nerve damage) and the extension of progression-free survival, while excellent tolerability was confirmed as most reported adverse events were mild to moderate.
Expansion of Precision Targeted Therapy Paradigm in the $1 Billion Global ALS Treatment Market
The current global Amyotrophic Lateral Sclerosis (ALS) treatment market is valued at approximately $1 billion and is showing an annual growth rate of 5-10%. Moving beyond the limitations of existing standard treatments like riluzole and edaravone (Radicava), which only delayed progression, the clinical efficacy of this second genetic subpopulation-targeted new drug—following the approval of Biogen's SOD1-targeted therapy tofersen (Qalsody)—is accelerating the transition toward customized precision medicine in the neurodegenerative disease sector.
Pursuit of Expedited Approval from Global Regulators and Acceleration of Commercialization via Licensing Partnership
Otsuka and Ionis plan to discuss fast-track and expedited approval pathways with global regulatory authorities, including the U.S. Food and Drug Administration (FDA), based on this phase 3 FUSION confirmatory data. Otsuka has secured worldwide exclusive development, manufacturing, and commercialization rights for Ulverensen from Ionis under the terms of a $10 million upfront payment and milestone-based royalties linked to net sales. With regulatory approval imminent, Otsuka is now fully preparing to activate its global distribution network and realize commercial revenue.
From an investor perspective, the success of this FUSION Phase 3 trial (p=0.0005) is a catalyst that dramatically increases the probability of regulatory approval for ulefnersen (ION363), prompting a revaluation of the mid-to-long-term pipeline value for Otsuka (4578) and Ionis (IONS). In the $1 billion global ALS treatment market, which had been shaken by the 2024 Phase 3 failure and market withdrawal of Relyvrio, the clinical validity of antisense oligonucleotides (ASOs) has once again been conclusively demonstrated following tofersen (Qalsody). From the perspective of researchers and the pharmaceutical industry, this study has redefined the benchmark for next-generation rare neurological drug development by demonstrating that precision therapy targeting a single gene mutation can substantially improve patient survival rates and serum NfL indicators. In the short term, key indicators include the schedule for the FDA accelerated approval application and whether an AdComm meeting will be held; in the long term, global drug pricing and the scale of post-launch royalty inflows will be critical.